$Amphastar Pharmaceuticals (AMPH.US)$🎯 On April 9, 2024, th...

New data: Q4 2023, revenue increased by 31.9%, operating profit increased by 42.7%, and net income increased by only 6.7% due to interest expenses and other income.

In 2023, revenue increased by 29.1%, operating profit increased by 83.3%, net income increased by 50.5%, and the return on equity increased to 23.6%.

Affected by the acquisition, the debt-to-asset ratio increased from 28.8% to 57.7%, with significant growth in total assets and net assets. Cash and accounts receivable on the asset side increased, mainly due to the increase in intangible assets. On the liability side, long-term borrowings increased to 0.59 billion, accounting for 92% of the net assets of 0.64 billion.

The current PE ratio is 15.8, which is significantly discounted compared to the recent growth rate, although the debt ratio is also high, the acquisition effect looks good, and the goodwill generated during the acquisition process is very small, with a low risk of intangible asset impairment, so it can still be chosen with caution (⭐️).